

Supplementary Materials for

Differential β -Arrestin-Dependent Conformational Signaling and Cellular Responses Revealed by Angiotensin Analogs

Brandon Zimmerman, Alexandre Beautrait, Benjamin Aguila, Ricardo Charles, Emanuel Escher, Audrey Claing, Michel Bouvier,* Stéphane A. Laporte*

*To whom correspondence should be addressed. E-mail: michel.bouvier@umontreal.ca (M.B.); stephane.laporte@mcgill.ca (S.A.L.)

Published 24 April 2012, *Sci. Signal.* **5**, ra33 (2012)
DOI: 10.1126/scisignal.2002522

The PDF file includes:

Fig. S1. Analog-induced production of IP₁ and recruitment of β -arrestin as analyzed by confocal microscopy and immunoprecipitation.

Fig. S2. Recruitment of β -arrestin to AT1R and conformational changes induced by AngII analogs.

Fig. S3. siRNA-mediated knockdown of GRK2 and GRK6.

Fig. S4. Role of GRK2 and GRK6 in the efficacy and potency on ligand-induced β -arrestin recruitment and conformational change.

Fig. S5. Dose-response relationship of ERK1/2 activation by AngII and analogs.

Fig. S6. Correlation plots between ligand affinity, BRET values, and ERK1/2 activation.

Table S1. IP₁ dose-response curve data used to calculate σ values and β factors.

Table S2. BRET dose-response data used to calculate σ values and β factors.




Figure S1. Analog-induced production of IP₁ and recruitment of β -arrestin as analyzed by confocal microscopy and immunoprecipitation.

A, HEK293 cells stably expressing HA-AT1R were used to measure IP₁ production downstream of the AT1R using CisBio's IP-one HTRF assay. Cells were treated with increasing concentrations of AngII or the analogs. AngII-induced production of IP₁ was set as the maximum. Data is representative of 3 independent experiments performed in duplicate. Statistical analysis was performed on maximal ligand concentration using a one-way ANOVA followed by a Dunnett's post-hoc test with untreated as control. *, $p < 0.05$, ***, $p < 0.001$. N.D. = Not determined. B, HA-AT1R cells transfected β arr2-YFP were stimulated with AngII (1 μ M) or analogs (10 μ M) for 15 min. Images are representative of 3 independent experiments. Scale bars are indicative of 10 μ m. C, HEK293 cells stably expressing HA-AT1R were stimulated for 15 min with either 1 μ M AngII or 10 μ M analog. Receptor immunoprecipitates were immunoblotted for β -arrestin and AT1R. Representative blot is shown. $n = 3$.




Fig. S2. Recruitment of β -arrestin to AT1R and conformational changes induced by AngII analogs.

BRET analysis showing dose-dependent agonist-promoted increased recruitment and conformational change of β arrestin to AT1R. A, Cells transfected with AT1R-YFP and β arr1-RlucII were stimulated with increasing concentrations of AngII and analogs for 25 min. The “x” represents the baseline signal from vehicle-treated cells. Data are the mean \pm S.E.M. of 3 independent experiments. Curves were fitted using nonlinear regression. B, Dose-dependent agonist-promoted decrease of β -arrestin intramolecular BRET. As in A, but cells were transfected with HA-AT1R and GFP10- β arr1-RlucII.




Figure S3. siRNA-mediated knockdown of GRK2 and GRK6.

Representative blot of GRK2 and GRK6 knockdown. Quantification of 3 independent experiments from cells used in BRET data presented in Fig. 3. Total ERK (tERK) was used as the loading control. One-way ANOVA followed by a Dunnett's post-hoc test was performed. ***, $p < 0.001$




Figure S4. Role of GRK2 and GRK6 in the efficacy and potency on ligand-induced β -arrestin recruitment and conformational change.

The $\log(EC_{50})$ and the efficacy of the analogs to induce β -arrestin recruitment (A) or conformational change (B) were subtracted between the GRK2 knockdown and control conditions. The data are presented as the change in potency and efficacy. The same analysis was performed in (C) and (D) respectively, in reference to GRK6 depleted cells compared to control cells.




Figure S5. Dose-response relationship of ERK1/2 activation by AngII and analogs.

Perkin Elmer's AlphaScreen technology was used to measure ERK1/2 activation triggered by increasing concentrations of AngII and the analogs. AngII-mediated activation of ERK1/2 was set as the maximum. Data is representative of 3 independent experiments done in duplicate. Statistical analysis was performed on maximal ligand concentration using a one-way ANOVA followed by a Dunnett's post-hoc test with untreated as control. *, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$, n.s., non-significant.




Figure S6. Correlation plots between ligand affinity, BRET values, and ERK1/2 activation.

A, Values of ERK1/2 activation at 15 min stimulation were correlated with the log of the K_i of binding. B, Values of ERK1/2 activation at 15 min stimulation were correlated with the efficacy of β arrestin recruitment to AT1R by BRET. C, Values of ERK1/2 activation at 15 min stimulation were correlated with the efficacy of β arrestin conformational change by BRET.

Table S1. IP₁ dose-response curve data used to calculate σ values and β factors.
n.d. = not determined

Ligand	E _{max}	LogK _i	log(τ)	SEM log τ	R ²
AngII	95.970	-8.938	0.919	0.068	0.981
SI	0.605	-8.155	n.d.	n.d.	0.451
SII	0.499	-6.672	n.d.	n.d.	0.353
SVdF	3.944	-8.101	0.513	0.109	0.852
SBpA	26.710	-7.749	0.863	0.079	0.918
DVG	1.078	-7.763	n.d.	n.d.	0.310

